Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Exploratory Phase 2a Randomized, Double-blind, Placebo-controlled Study of Dipraglurant (ADX48621) Immediate Release Tablets in Patients With Blepharospasm

NCT05027997 is registered in ClinicalTrials.gov with Addex Pharma S.A. as lead sponsor.

NCT NCT05027997
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05027997 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Exploratory Phase 2a Randomized, Double-blind, Placebo-controlled Study of Dipraglurant (ADX48621) Immediate Release Tablets in Patients With Blepharospasm
Lead sponsor
Addex Pharma S.A.
Phase
Phase 2
Overall status
Completed
Start date
October 6, 2021
Completion date
November 27, 2022
Enrollment
15 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

blepharospasm, dystonia